A protected cyclic hexapeptide (XVI), cyclo-(diglycyl-ε-benzyloxycarbonyl-l-lysyl)2, was synthesized in three different ways; the cyclization reactions of a protected tripeptide azide, a protected tripeptide active ester, and a protected hexapeptide active ester produced the protected cyclic hexapeptide (XVI) in fairly good yields. The product (XVI) was then converted by hydrogenolysis to the cyclic hexapeptide (XVII), cyclo-(digrycyl-l-lysyl)2. It was found that the cyclic hexapeptide was hydrolyzed slowly by trypsin to a tripeptide diglycyl-lysine, whereas a synthetic hexapeptide, diglycyl-lysyl-diglycyl-lysine, was hydrolyzed very rapidly to the tripeptide.
No takes yet. Share an insight, caveat, or question.
Abe et al. (1967) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: